Amsterdam/Houten, 14 November 2022 – Our portfolio company AMP Group joins forces with medical logistics company 2MC. By working together, which in part has been made possible by Holland Capital, the organization is significantly expanding its position in the medical logistics market. With 2MC, AMP Group is taking its third step in its buy-and-build strategy.
2MC
2MC specialises in transporting diagnostic material (e.g. blood, tissues, smear tests) from general practitioners and other medical institutions to laboratories throughout the Netherlands. The company provides transport for pathology, medical microbiology and clinical chemistry. 2MC also transports Covid-19 samples from test locations to laboratories and supplies Covid-19 vaccines and test materials.
The medical logistics market
AMP Group is fully committed to the safe and refrigerated delivery of medicines and valuable products where strict safety requirements, such as identification, must be met. The collaboration with 2MC is the third acquisition in AMP Group’s buy-and-build strategy. Late 2021, AMP Group and Delta Logistics started their collaboration, Delta Logistics is a large independent logistics B2B solutions provider, specialized in active refrigerated delivery of pharmaceutical and veterinary products throughout the Netherlands. Mid 2022, Omega Logistics was acquired by AMP Group. Omega Logistics is a specialized logistics service provider that operates mainly in the pharmaceutical and healthcare sector. With these three acquisitions, AMP Group has attained a leading position in the rapidly growing medical logistics market (B2B and B2C).
Marco van der Klij, Managing Director of AMP Group: “By joining forces with 2MC, we as a group can continue to broaden our logistics services within the medical market. The logistics for diagnostic material are usually arranged in such a way that the collected samples can be processed by the laboratory on the same day. With 2MC on board, we now also have a solution for this. We also see opportunities to use these services for non-medical laboratories.”
Ruud Koreman, General Manager of 2MC: “We have been looking for opportunities to expand in the medical transport segment, for both B2B and B2C. We have found a strong partner in AMP Group with whom we can realize our growth ambitions. We look forward to leveraging the new opportunities that this collaboration will open up for veterinary and non-medical labs.”
Holland Capital has been actively involved as a shareholder in AMP Group since the end of 2020.
About 2MC
For over twenty years, 2MC has specialized in transporting diagnostic material between medical institutions and laboratories. The organization arranges, among other things, the logistics for the cervical cancer population screening throughout the Netherlands. Fragile materials, such as the Covid-19 vaccines, are transported in a temperature-controlled vehicle, which is either cooled or at room temperature. 2MC offers easy and interesting work for pensioners, who usually find this courier work a nice way to contribute to society while earning some extra money.
About AMP Group
Over the past twenty years, AMP Group has grown from a start-up to a mature company that works for leading customers such as T-Mobile, KPN, Kiwa, ABN-AMRO, International Card Services, hospitals, pharmacies, medical wholesalers and over sixty municipalities. Among other services, AMP Group delivers medicines, telephones and confidential documents that require recipient identification. In addition to its proprietary customer experience and route planning software, the company uses the latest technology in ID authentication, facial recognition and biometric signatures to accurately identify the recipient.
About Holland Capital
Holland Capital has invested responsibly and successfully in more than 150 Dutch SMEs over the past 40 years. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team understand entrepreneurship. They aim to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful Healthcare and Technology entrepreneurs.
Holland Capital looks back on a positive 2025
This year again, Holland Capital has taken important steps within the Technology and Healthcare sectors. Our clear investment strategy, combined with close and active collaboration with entrepreneurs and advisors, has resulted in the further expansion of our portfolio and strong progress within our Holland Capital Growth & Buy-Out Fund V.
Adjust expands advisory proposition with acquisition of Accent Advies
Our portfolio company Adjust Consulting (Adjust) is expanding its advisory proposition with the acquisition of Accent Advies.
Emixa acquires Nextage Group to further strengthen its presence and focus on Digital Thread leadership in the Nordics
Our portfolio company Emixa, a leading European digital transformation consultancy and trusted partner for Siemens, SAP, Mendix and integration technologies, today announced the acquisition of Nextage Group, one of the most respected Siemens Digital Industries Software partners in the Nordic region.
Semalytix Secures €5.7 Million to Scale its Agentic AI Platform
Semalytix, a leader in Agentic AI for pharmaceutical patient intelligence, today announced the successful closing of its €5.7 million growth round.
HMCC Completes Add-On Investment in CareAbout
Our portfolio company HMCC proudly announces the successful completion of an add-on investment in CareAbout. This step brings together two strong organizations, joining forces to further support healthcare providers in ensuring continuity of care.
Abilia acquires portfolio company LivAssured
Abilia, a subsidiary of MedCap AB (publ) and part of Business Area Assistive Tech, has signed an agreement to acquire Holland Capital’s portfolio company LivAssured B.V.
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 311 94 11
Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 43 63 69 01





